Related Experiment Videos

Oral high-dose phenobarbital therapy for early infantile epileptic encephalopathy

Hiroshi Ozawa1, Yuko Kawada, Seiji Noma

  • 1Department of Pediatrics, Tokyo Metropolitan Hachioji Children's Hospital, Hachioji, Tokyo, Japan.

Pediatric Neurology
|April 17, 2002
PubMed

Insights

High-dose phenobarbital effectively treated a patient with Ohtahara syndrome, significantly reducing seizures and epileptic discharges. This therapy is a promising option for early infantile epileptic encephalopathy with suppression bursts.

Area of Science:

  • Neurology
  • Pediatric Neurology
  • Epileptology

Background:

  • Early infantile epileptic encephalopathy with suppression bursts (Ohtahara syndrome) is a severe, rare epilepsy syndrome.
  • Treatment options for Ohtahara syndrome are limited, with variable responses to conventional antiepileptic drugs.

Observation:

  • A 1-month-old infant presented with frequent tonic spasms characteristic of Ohtahara syndrome.
  • Initial treatments including intravenous midazolam and various oral antiepileptic drugs showed minimal efficacy.

Findings:

  • Oral high-dose phenobarbital therapy (15 mg/kg/day) dramatically reduced seizure frequency from approximately 300 to 5-10 per day.
  • Electroencephalogram showed a significant decrease in epileptic discharges with therapeutic serum phenobarbital levels (60-100 mg/dL).

Implications:

  • High-dose phenobarbital is a viable and effective treatment strategy for Ohtahara syndrome.
  • This approach warrants consideration in managing early infantile epileptic encephalopathy with suppression bursts.
  • Further research into optimal dosing and long-term outcomes of high-dose phenobarbital in Ohtahara syndrome is recommended.

Related Concept Videos